THALES
10.9.2019 09:32:03 CEST | Business Wire | Press release
Thales today announced that Treezor, the leading banking-as-a-service platform in France, has deployed its SafeNet Data Protection On Demand solution to provide security across its entire payment chain, from tier one banks and neo-banks to crowdfunding organizations.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190910005069/en/
As an electronic money issuer, Treezor is bound by a variety of data privacy regulations and requirements, including requirements from the French Regulator (ACPR), the Mastercard network and the European Union’s General Data Protection Regulation (GDPR). Treezor is required to implement strong data security controls to protect personal financial information and other sensitive data. After evaluating several providers, Treezor selected SafeNet Data Protection On Demand (DPoD) due to its ability to provide a cost-effective and easy-to-use cloud HSM service as a highly secure root of trust for cryptographic operations.
“Innovation is the lifeblood of how we operate, but it should never come at the expense of security or vice versa,” said Eric Lassus, CEO of Treezor . “Part of our ethos is to work extremely closely with our clients to understand their needs, which led to the creation of our payment platform using standard APIs. As a result, we need a solution that meets our security, management and commercial needs.”
Treezor, recently acquired by Societe Generale, was familiar with the security advantages of HSMs, but wanted to minimize investments and on-going overheads, so it began investigating cloud-based offerings. Taking advantage of the 30-day free evaluation offered by Thales for its cloud-based HSM solution, Treezor was impressed by the ease of use and the speed it was able to deploy its test environment. During the evaluation phase of SafeNet Data Protection On Demand, the ‘point-and-click’ ease of use convinced Treezor that SafeNet Cloud HSM On Demand service provided the best solution in terms of cost, security and ease of implementation.
With SafeNet Data Protection On Demand, Treezor benefits from:
- Rapid deployment and easy integration – Cloud HSM services were up and running and integrated into their systems in minutes
- Service Level Availability – Unlike other Cloud HSM services on the market, SafeNet Data Protection On Demand comes with a 99.95% SLA
- Predictable costs – Pricing is provided in a predictable way with all costs like redundancy and back-up services inclusive, meaning no hidden charges for high availability
Treezor’s strategy has led to a dramatic growth in two years, from issuing 100,000 cards and €400,000 of transactions in 2017 to over 500,000 cards and €5 billion in 2018.
With the scalability of SafeNet Cloud HSM On Demand, alongside its separation of duties, Treezor can offer each customer their own dedicated HSM service, bringing them safety in the knowledge that their financial and other sensitive data is segregated and protected.
“Working in the financial sector, trust is an extremely high parameter with which companies are judged by customers,” Lassus continued. “We chose Thales because of its stellar reputation in security, the ease-of-use of the whole solution and the high SLAs it guarantees. It’s vital too that we’re able to give our customers a clear insight into costs and availability of our services. The transparency and reliability we’ve received with SafeNet Data Protection On Demand is ideal for our needs of offering services simply, secure and costs effectively across our entire payment chain, from traditional banks to the most innovative fintech companies.”
Todd Moore, vice president of encryption products for cloud protection and licensing activity at Thales said: “The financial industry is one of the most regulated in the world, so it can sometimes be tricky for some to find that balance between innovation and compliance. With SafeNet Data Protection on Demand, Treezor can offer innovative solutions across its payment platform, while ensuring a transparent and secure approach that satisfies both regulators and customers.”
About Thales The people we all rely on to make the world go round – they rely on Thales. Our customers come to us with big ambitions: to make life better, to keep us safer. Combining a unique diversity of expertise, talents and cultures, our architects design and deliver extraordinary high technology solutions. Solutions that make tomorrow possible, today. From the bottom of the oceans to the depth of space and cyberspace, we help our customers think smarter and act faster - mastering ever greater complexity and every decisive moment along the way. With 80,000 employees in 68 countries, Thales reported sales of €19 billion in 2018.
About Treezor Founded in 2016 by Éric Lassus and Xavier Labouret, Treezor is a French Bank-as-a-Service platform covering the entire payment chain through API based solutions. The fintech is an approved electronic money issuer and a Mastercard principal member. As a young and innovative company, Treezor devotes a significant part of its resources to develop new technologies in the field of open banking to support the strategy and service deployment of its customers. |
PLEASE VISIT
Thales Group
Digital Security
Download HD photos
View source version on businesswire.com: https://www.businesswire.com/news/home/20190910005069/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
